Pembrolizumab (new indication: gastric cancer with MSI-H or dMMR tumors, pretreated patients)



  • Active Sustance: Pembrolizumab
  • Name: Keytruda®
  • Therapeutic area: Gastric cancer
  • Pharmaceutical company: MSD Sharp & Dohme GmbH


Time table:

  • Start: 01.08.2022
  • Publication of assessment: 01.11.2022
  • End of public hearing: 22.11.2022
  • Final decision by G-BA: middle of January 2023


Comparative therapy:

  1. Adults with disease progession during or after therapy: Therapy at the physician's discretion, appropriate therapies include:
    - irinotecan OR
    - docetaxel OR
    - paclitaxel OR
    - ramucirumab in combination with paclitaxel
  2. Adults with disease progression during or after at least two previous therapies: Trifluridine/tipiracil